Deep Brain Stimulation Surgery: Indications, Contraindications, and Perioperative Considerations
Deep brain stimulation (DBS) is indicated for patients with Parkinson's disease who have motor fluctuations and excellent L-dopa sensitivity (≥50%), medically refractory obsessive-compulsive disorder, and select cases of dystonia, essential tremor, and epilepsy, with absolute contraindications including lack of L-dopa responsiveness, severe cognitive impairment, and active neuropsychiatric disorders.
Primary Indications
Parkinson's Disease (Most Robust Evidence)
For advanced PD with motor fluctuations:
- Patients must demonstrate ≥50% improvement on preoperative L-dopa testing 1
- Motor symptoms present for at least 4 years with documented fluctuations 1
- STN-DBS (subthalamic nucleus) provides large improvements in quality of life, motor symptoms, dyskinesia, and gait freezing 1
For early PD (patients <60 years):
- Requires at least mild motor fluctuations with excellent L-dopa sensitivity
- Normal psychiatric and cognitive status mandatory
- Quality of life must be relevantly reduced despite good medication response 1
- Critical pitfall: STN-DBS is NOT recommended for non-fluctuating patients, as studies show no significant benefit 1
Obsessive-Compulsive Disorder
Bilateral STN-DBS is recommended over best medical management for medically refractory OCD (Level I evidence) 2
- Nucleus accumbens or bed nucleus of stria terminalis DBS may also be used (Level II evidence) 2
- Insufficient evidence exists to identify the most effective target 2
Other Movement Disorders
- Essential tremor: Vim (ventral intermediate nucleus) DBS for tremor-predominant cases 3
- Dystonia: GPi (globus pallidus internus) targeting 4
- Epilepsy: Established indication with lower readmission rates (4.4% at 30 days) compared to PD 4
Absolute Contraindications
For all DBS procedures:
- Lack of L-dopa sensitivity at high dosages 1
- Severe cognitive impairment or dementia 1
- Active severe neuropsychiatric disorders 1
- Neurosurgical contraindications (coagulopathy, inability to tolerate surgery) 1
Target-specific contraindications:
- LCIG (levodopa-carbidopa intestinal gel): Conditions interfering with PEG tube placement or gastrointestinal absorption 1
- CAI (continuous apomorphine infusion): ECG alterations, hemolytic anemia, local skin infections, severe orthostatic hypotension 1
Relative Contraindications and Risk Factors
- Advanced age and multimorbidity significantly limit operability and outcomes 1
- Mild psychiatric symptoms constitute relative contraindications for all invasive treatments 1
- Age considerations: While age limits exist for STN-DBS, they have not been scientifically validated 1
Perioperative Considerations
Preoperative Assessment
Mandatory evaluations:
- Formal L-dopa challenge test documenting ≥50% improvement 1
- Comprehensive neuropsychological testing to exclude cognitive impairment 5, 6
- Psychiatric evaluation to identify active mood disorders or psychosis 5
- Documentation of motor fluctuations (diaries, objective assessments) 1
Patient selection factors:
- Specific parkinsonian motor indications (tremor, bradykinesia, gait dysfunction) 5
- Previous medical therapies and adverse effects 5
- Exclude atypical parkinsonisms through careful differential diagnosis 5
Surgical Technique Options
Traditional awake surgery 3:
- Stereotactic frame application with CT/MRI imaging
- Anatomical targeting via direct MRI visualization
- Physiological verification through microelectrode recording (MER)
- Intraoperative test stimulation to assess benefits and side effects
Emerging asleep techniques 7, 8:
- Frameless stereotaxy with robotic guidance
- Intraoperative MRI for electrode placement verification
- General anesthesia increasingly used with advanced imaging
- 30% of patients may require intraoperative lead adjustments 8
Anesthesia Management
- Awake surgery traditionally preferred for physiological monitoring 3
- General anesthesia acceptable with advanced imaging guidance 7
- For patients with existing DBS undergoing unrelated surgery: Anesthesiologists must understand device management and potential complications 7
Adverse Events and Complications
Surgery-Related Complications
- Hemorrhagic complications: Rare but serious (0% in recent series) 8
- Infection: Approximately 2% requiring reoperation 8
- Lead migration: Rare, may require late reoperation 8
- Intraoperative adjustments: 30% of cases, with 47% requiring trajectory changes 8
Target-Specific Adverse Events
- STN-DBS: Dysarthria, gait impairment, neuropsychiatric symptoms 1
- GPi-DBS: Visual side effects from optic tract stimulation (requires depth adjustment) 8
- Device-related: Neurostimulator revision needed in 11.5% of PD patients within 30 days 4
Neuropsychiatric Outcomes
- Transient delirium: 18% of PD patients postoperatively 8
- Cognitive decline: Small reductions at 6 months in 22% of PD patients, correlating with advanced age 8
- Quality of life: Most PD patients show improvements in mood and quality of life despite minor cognitive changes 8
Readmission Rates by Indication
30-day readmission rates vary significantly 4:
- Parkinson's disease: 15.5% (highest)
- Essential tremor: 7.8%
- Epilepsy: 4.4% (lowest)
- Dystonia: intermediate rates
Common readmission causes:
- Device revision surgery (11.5% for PD within 30 days) 4
- Pneumonia (particularly in PD, seizure, and dystonia patients) 4
- Dysphagia (more common in ET, seizure, and dystonia than PD) 4
Clinical Algorithm for Patient Selection
- Confirm diagnosis: Rule out atypical parkinsonisms
- Document L-dopa responsiveness: Must show ≥50% improvement
- Verify motor fluctuations: Well-documented, at least mild severity
- Screen for contraindications: Cognitive testing, psychiatric evaluation
- Assess surgical candidacy: Age, comorbidities, operability
- Define therapeutic goals: Quality of life optimization, symptom control
- Select target: STN for PD with fluctuations, GPi for dystonia, Vim for tremor
Critical pitfall: DBS has the strongest long-term evidence among invasive therapies; pump therapies (LCIG, CAI) lack robust long-term controlled data 1.